<?xml version="1.0" encoding="UTF-8"?>
<p>The vicious circle between vascular damage, lung damage, inflammation, and immune paralysis can rapidly be responsible for fatalities, especially when patients cannot endure the challenge of the infection on vital functions, because of comorbidities (
 <xref ref-type="fig" rid="vaccines-08-00224-f002">Figure 2</xref>). Acute respiratory distress syndrome (ARDS) can result from alveolar cell damage and lung inflammation and can be worsened by ACE2 depletion, lung vasculopathy with micro-thrombosis [
 <xref rid="B95-vaccines-08-00224" ref-type="bibr">95</xref>]. The diseased respiratory environment is also exposed to the risk from secondary bacterial or fungal infections, which can precipitate a fatal course of the infection [
 <xref rid="B7-vaccines-08-00224" ref-type="bibr">7</xref>]. Heart or kidney failure can also occur in severe cases [
 <xref rid="B96-vaccines-08-00224" ref-type="bibr">96</xref>]. A crucial aspect of the disease is coagulopathy that can accelerate the progression toward multiorgan failure [
 <xref rid="B97-vaccines-08-00224" ref-type="bibr">97</xref>]. Vasculopathy and coagulopathy are probably related to the infection of endothelial cells by SARS-CoV-2 [
 <xref rid="B31-vaccines-08-00224" ref-type="bibr">31</xref>,
 <xref rid="B98-vaccines-08-00224" ref-type="bibr">98</xref>], but it could be worsened by the development of vasculitis, with the production of autoantibodies, such as antiphospholipid, and activation of complement [
 <xref rid="B79-vaccines-08-00224" ref-type="bibr">79</xref>,
 <xref rid="B80-vaccines-08-00224" ref-type="bibr">80</xref>,
 <xref rid="B99-vaccines-08-00224" ref-type="bibr">99</xref>].
</p>
